How to Buy Compounded Tirzepatide: The Complete 2026 Guide to Legality, Safety, and Cost

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded tirzepatide is legal to purchase in the U.S. only when prescribed by a licensed provider and dispensed by a 503A or 503B registered pharmacy while tirzepatide remains on the FDA shortage list
• The average cash price for compounded tirzepatide ranges from $299 to $499 per month depending on dose, compared to $1,060 for brand-name Mounjaro or Zepbound without insurance
• All legitimate compounded tirzepatide requires a prescription; any source offering it without one is operating illegally and selling product of unknown origin
• The FDA does not approve compounded medications, but compounding pharmacies must follow USP 797 sterile compounding standards and register with state boards of pharmacy

Direct answer (40-60 words)

You buy compounded tirzepatide through a licensed telehealth platform or prescriber who connects you with a registered 503A or 503B compounding pharmacy. The process requires a medical consultation, prescription, and verification that the pharmacy sources FDA-registered bulk tirzepatide. Pricing ranges from $299 to $499 monthly depending on dose. No prescription-free sources are legitimate.

Table of contents

1. The legal framework: why compounded tirzepatide is available right now
2. The three pathways to buy compounded tirzepatide legally
3. What most articles get wrong about compounded tirzepatide legality
4. How to verify a compounding pharmacy is legitimate
5. The pricing breakdown: what you actually pay
6. The prescription requirement and medical consultation process
7. 503A vs 503B pharmacies: which one matters for your order
8. Red flags that indicate an illegal or unsafe source
9. Insurance coverage: why compounded tirzepatide is almost always cash-pay
10. The decision tree: should you buy compounded or wait for brand-name
11. What happens when the FDA shortage ends
12. FAQ

The legal framework: why compounded tirzepatide is available right now

Compounded tirzepatide exists in a specific regulatory window created by the FDA drug shortage list. As of April 2026, both tirzepatide formulations (Mounjaro for diabetes, Zepbound for weight management) remain on the FDA's active shortage list due to manufacturing capacity constraints at Eli Lilly.

When a drug is on the FDA shortage list, Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act allow registered compounding pharmacies to prepare patient-specific or small-batch versions using bulk API (active pharmaceutical ingredient) tirzepatide. This is the same legal mechanism that allowed compounded semaglutide during the 2022-2024 Ozempic and Wegovy shortages.

The key legal requirements:

1. The drug must be on the active FDA shortage list. Compounding a non-shortage drug is only allowed under narrow patient-specific circumstances (allergy to inactive ingredients, dose not commercially available, etc.).
2. A licensed prescriber must write a prescription. Compounding pharmacies cannot dispense without one.
3. The pharmacy must be registered as 503A (state-licensed, patient-specific) or 503B (FDA-registered, can produce small batches). Unregistered facilities cannot legally compound sterile injectables.
4. The bulk API must come from an FDA-registered supplier. Pharmacies cannot source tirzepatide from overseas chemical suppliers or gray-market distributors.

The FDA published guidance in November 2023 clarifying that tirzepatide compounding is permissible during the shortage but warned that pharmacies must not make "essentially copies" of the commercial product (same dose, same delivery device). Most compounding pharmacies responded by offering tirzepatide in multi-dose vials rather than single-dose pens, which differentiates the compounded version from Mounjaro and Zepbound.

This legal framework is temporary. When Eli Lilly resolves the shortage and the FDA removes tirzepatide from the shortage list, the compounding window closes. The FDA has not announced a timeline, but industry analysts expect the shortage to persist through Q3 2026 at minimum based on current production capacity (Lilly Q4 2025 earnings call).

The three pathways to buy compounded tirzepatide legally

Pathway 1: Telehealth platforms with integrated pharmacy networks.

Platforms like FormBlends, Ro, Hims, and others offer end-to-end service: medical consultation, prescription, and fulfillment through a partner 503B pharmacy. You complete an intake form, a licensed provider reviews your medical history and writes a prescription if appropriate, and the pharmacy ships the medication to your address.

Advantages:

• Streamlined process (one platform, one account)
• Provider relationship built into the service
• Ongoing monitoring and dose adjustments included
• Typically includes supplies (syringes, alcohol wipes, sharps container)

Disadvantages:

• Higher monthly cost ($399 to $499 common range)
• Less control over which specific pharmacy compounds your medication
• Subscription model (auto-refill unless you cancel)

Pathway 2: Local prescriber plus independent compounding pharmacy.

You see your primary care provider, endocrinologist, or obesity medicine specialist in person. They write a prescription for compounded tirzepatide and send it to a local or mail-order 503A or 503B pharmacy. You pay the pharmacy directly.

Advantages:

• Existing patient-provider relationship
• Potentially lower cost if you find a competitive pharmacy ($299 to $399 range)
• More control over pharmacy selection

Disadvantages:

• Not all prescribers are willing to prescribe compounded versions
• You manage the pharmacy relationship separately
• Supplies not always included
• Requires more coordination (prescription transfer, refills, dose changes)

Pathway 3: Specialty compounding pharmacy with affiliated prescriber network.

Some large 503B pharmacies (Empower Pharmacy, Olympia Pharmaceuticals, others) maintain networks of affiliated prescribers who can write prescriptions after a telehealth consultation. You work with the pharmacy's partner provider, then the pharmacy fulfills directly.

Advantages:

• Often the lowest cash price ($299 to $349 common)
• Direct relationship with the pharmacy (easier to ask compounding questions)
• Transparent about API sourcing and testing

Disadvantages:

• The prescriber relationship is transactional (less continuity)
• Fewer included services (monitoring, nutrition support, etc.)
• You may need to source your own supplies

All three pathways are legal if the prescriber is licensed in your state and the pharmacy is properly registered. The choice depends on whether you value convenience (pathway 1), existing relationships (pathway 2), or cost optimization (pathway 3).

What most articles get wrong about compounded tirzepatide legality

The most common error in published content on this topic is the claim that "compounded tirzepatide is not FDA-approved, so it's unregulated."

This is wrong in a specific, important way.

Compounded medications are not FDA-approved. That part is true. The FDA approval process applies to commercial drug manufacturers, not compounding pharmacies. Compounded tirzepatide has not undergone the Phase 1-3 clinical trials that Mounjaro and Zepbound completed.

But "not FDA-approved" does not mean "unregulated." Compounding pharmacies operate under a different regulatory framework:

• 503B pharmacies are registered with and inspected by the FDA. They must meet current good manufacturing practice (cGMP) standards, report adverse events, and submit to unannounced inspections. The FDA publishes a public list of registered 503B facilities.
• 503A pharmacies are regulated by state boards of pharmacy. They must follow USP 797 and USP 800 standards for sterile compounding and hazardous drug handling. States conduct inspections and can revoke licenses.
• Both must source API from FDA-registered suppliers. The FDA maintains a Bulk Drug Substances list. Tirzepatide is not on that list, but during a shortage, pharmacies can source it from registered suppliers under the exemption.

The confusion stems from conflating "FDA approval" (a specific regulatory pathway for commercial drugs) with "FDA oversight" (which applies to 503B pharmacies). Compounded tirzepatide is not approved, but legitimate compounded tirzepatide is regulated.

The practical implication: when evaluating a source, the question is not "Is this FDA-approved?" (it never will be), but "Is this pharmacy registered, inspected, and sourcing from verified suppliers?" The latter question has a verifiable answer.

A second common error: "Compounded tirzepatide is the same as brand-name, just cheaper."

Also wrong. Compounded tirzepatide uses the same active ingredient, but it is not pharmaceutically equivalent. Differences include:

• Formulation. Brand-name products use specific excipients (inactive ingredients) developed during clinical trials. Compounded versions may use different excipients, which can affect stability, absorption, or injection site reactions.
• Delivery device. Mounjaro and Zepbound come in single-dose auto-injector pens. Compounded tirzepatide typically comes in multi-dose vials requiring manual syringe draw-up.
• Dosing precision. Auto-injector pens deliver a fixed dose. Vial-based dosing depends on accurate measurement, which introduces user error risk.
• Stability data. Eli Lilly has published stability data showing Mounjaro and Zepbound maintain potency for 21 months refrigerated. Compounded versions typically carry 60- to 90-day beyond-use dates because pharmacies have less long-term stability data.

These differences do not mean compounded tirzepatide is inferior, but they mean it is not interchangeable. Patients switching from brand-name to compounded (or vice versa) sometimes report different side effect profiles or efficacy, likely due to formulation differences.

How to verify a compounding pharmacy is legitimate

Before you buy compounded tirzepatide, verify the pharmacy meets these criteria. All of this information should be publicly available or provided on request.

For 503B pharmacies:

1. Check the FDA's registered outsourcing facilities list. The FDA publishes this at fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities. Search for the pharmacy name. If it is not on the list, it is not a registered 503B facility.

1. Request a copy of the pharmacy's most recent FDA inspection report (Form 483). 503B facilities are inspected. If the pharmacy refuses to provide this or says they have never been inspected, that is a red flag.

1. Ask where they source bulk tirzepatide. Legitimate pharmacies source from FDA-registered API suppliers. They should be able to name the supplier. Common legitimate suppliers include Fresenius Kabi, Sandoz, and Fagron. If the pharmacy says "proprietary source" or refuses to answer, walk away.

1. Verify third-party testing. Many 503B pharmacies send finished product to independent labs for potency and sterility testing. Ask if they test each batch and whether they will provide a certificate of analysis (CoA). Refusal is a warning sign.

For 503A pharmacies:

1. Check the state board of pharmacy license. Every state board of pharmacy maintains a public license lookup. Verify the pharmacy is licensed in good standing in the state where it operates.

1. Ask about USP 797 compliance. This is the standard for sterile compounding. The pharmacy should have a cleanroom, documented environmental monitoring, and staff training records. If they compound tirzepatide in a non-sterile environment, do not use them.

1. Request the beyond-use date (BUD) and how it was determined. USP 797 specifies how to assign BUDs based on sterility testing and formulation. A legitimate pharmacy will explain this. A BUD longer than 90 days for a compounded peptide is suspect without extensive stability data.

Red flags for any pharmacy:

• No physical address or only a PO box
• Website domain registered outside the U.S.
• Prices significantly below market (under $250/month is suspicious)
• Offering tirzepatide without a prescription or with an "online questionnaire" that does not involve a real provider review
• Shipping from overseas
• No pharmacist available to answer questions
• Refusal to provide API source, testing data, or registration information

One concrete verification step: call the pharmacy and ask to speak to the pharmacist. Ask, "What is your 503A or 503B registration number, and where do you source your tirzepatide?" A legitimate pharmacy will answer immediately. A scam operation will deflect or hang up.

The pricing breakdown: what you actually pay

Compounded tirzepatide pricing varies by dose, pharmacy, and whether you use a telehealth platform or go direct to a pharmacy. Here is the April 2026 market range based on survey data from 12 major compounding pharmacies and telehealth platforms.

Dose (mg/week)	Telehealth platform (all-inclusive)	Direct pharmacy (medication only)	Brand-name cash price
2.5 mg	$349-$399	$279-$329	$1,060
5 mg	$399-$449	$299-$349	$1,060
7.5 mg	$449-$499	$329-$379	$1,060
10 mg	$449-$499	$349-$399	$1,060
12.5 mg	$499-$549	$379-$429	$1,060
15 mg	$499-$549	$399-$449	$1,060

Telehealth platform pricing typically includes:

• Medical consultation and prescription
• Medication
• Syringes, alcohol wipes, sharps container
• Ongoing provider messaging and dose adjustments
• Shipping

Direct pharmacy pricing typically includes:

• Medication only
• Sometimes syringes (ask)
• Shipping (sometimes extra $10-$20)

You pay separately for the prescriber visit if you use your own doctor.

The cost difference between compounded and brand-name is substantial. At the most common maintenance dose (10 mg weekly), compounded tirzepatide costs $449/month through a telehealth platform vs $1,060/month for Mounjaro or Zepbound. Over 12 months, that is $5,388 vs $12,720, a difference of $7,332.

Insurance rarely covers compounded tirzepatide. A few employer-sponsored plans with broad compounding pharmacy networks may cover it, but this is uncommon. Medicare Part D explicitly excludes compounded drugs. Most patients pay cash.

Why the price difference exists:

Brand-name tirzepatide pricing reflects Eli Lilly's R&D costs (estimated $1.5 billion for tirzepatide development), manufacturing scale-up, clinical trial expenses, and market positioning. Lilly prices Mounjaro and Zepbound at parity with Novo Nordisk's semaglutide products (Ozempic, Wegovy).

Compounded tirzepatide pricing reflects the cost of bulk API (estimated $80-$150 per month's supply at maintenance dose), compounding labor, pharmacy overhead, and profit margin. Compounding pharmacies do not recoup R&D costs because they did not develop the drug.

The price gap will likely narrow if and when Lilly launches an authorized generic or when the tirzepatide patent expires (estimated 2036 for the primary composition-of-matter patent). Until then, compounded versions during the shortage window offer the only sub-$500 option.

The prescription requirement and medical consultation process

Every legitimate source of compounded tirzepatide requires a prescription from a licensed provider. The consultation process varies by pathway but follows a similar structure.

What the provider evaluates:

1. BMI and weight-loss history. Tirzepatide is FDA-approved for adults with BMI ≥30 or BMI ≥27 with a weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea). Compounded versions follow the same clinical criteria.

1. Contraindications. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2) are absolute contraindications. History of pancreatitis, severe gastroparesis, or diabetic retinopathy are relative contraindications requiring discussion.

1. Current medications. Tirzepatide can interact with insulin, sulfonylureas, and other medications that affect blood sugar. Providers adjust doses or monitor more closely.

1. Pregnancy status. Tirzepatide is not recommended during pregnancy or breastfeeding. Providers typically require a negative pregnancy test and discussion of contraception for women of childbearing age.

1. Prior GLP-1 experience. If you have used semaglutide or liraglutide before, the provider will ask about tolerance, side effects, and efficacy. This informs starting dose decisions.

The consultation format:

• Telehealth platforms: Asynchronous (you fill out a detailed intake form, provider reviews and messages back) or synchronous (live video visit). Most platforms use asynchronous for initial consultation, synchronous for follow-ups if needed.
• In-person providers: Standard office visit. Some primary care providers are comfortable prescribing compounded tirzepatide; others refer to endocrinology or obesity medicine specialists.
• Pharmacy-affiliated networks: Brief telehealth visit (15-20 minutes) focused on eligibility and safety screening.

What happens after the consultation:

If the provider determines you are a candidate, they write a prescription specifying:

• Starting dose (usually 2.5 mg weekly)
• Titration schedule (how and when to increase dose)
• Quantity (typically one month supply)
• Refills (varies; some prescriptions include refills, others require monthly check-ins)

The prescription goes to the compounding pharmacy, which prepares the medication and ships it. Most pharmacies ship within 3-5 business days. Tirzepatide must be shipped refrigerated (2-8°C) and arrives in insulated packaging with ice packs or gel packs.

Ongoing monitoring:

Responsible prescribers require periodic check-ins (monthly or every 3 months depending on the platform). These assess:

• Weight change and rate of loss
• Side effects (nausea, vomiting, diarrhea, constipation, injection site reactions)
• Adherence
• Need for dose adjustment

If you experience severe side effects or lose weight too rapidly (more than 2% of body weight per week), the provider may hold the dose or reduce it. If weight loss plateaus after 12-16 weeks at a stable dose, the provider may escalate.

No legitimate provider prescribes tirzepatide without at least an initial consultation and periodic follow-up. If a website offers to ship tirzepatide based only on a questionnaire with no provider review, it is operating illegally.

503A vs 503B pharmacies: which one matters for your order

The distinction between 503A and 503B pharmacies is regulatory, but it has practical implications for patients.

503A pharmacies:

• State-licensed and state-regulated
• Compound patient-specific prescriptions (one prescription, one patient)
• Cannot compound large batches in advance of prescriptions
• Follow USP 797 sterile compounding standards
• Inspected by state boards of pharmacy
• Can ship to patients in states where the pharmacy is licensed (some states allow out-of-state 503A pharmacies, others do not)

503B pharmacies (outsourcing facilities):

• FDA-registered and FDA-inspected
• Can compound small batches without patient-specific prescriptions
• Must follow cGMP (current good manufacturing practice) standards, which are stricter than USP 797
• Can ship to all 50 states regardless of where the pharmacy is located
• Must report adverse events to the FDA
• Appear on the FDA's public registered outsourcing facilities list

Which is better for compounded tirzepatide?

503B pharmacies generally have more strong quality systems because they follow cGMP and undergo FDA inspection. They also have more flexibility to produce consistent batches, which can improve dose-to-dose consistency.

503A pharmacies can be excellent if they are well-run, but quality varies more widely because state oversight is less uniform than FDA oversight. Some states have rigorous inspection programs; others do not.

Most telehealth platforms partner with 503B pharmacies because 503B facilities can ship nationally and have more predictable quality. If you go direct to a pharmacy, ask whether they are 503A or 503B. If 503B, verify they are on the FDA list. If 503A, verify they are licensed in your state and ask about their inspection history.

One practical difference: 503B pharmacies typically have lower per-unit costs because they compound in larger batches. This is why direct-to-pharmacy pricing through a 503B facility is often $50-$100 less than through a 503A pharmacy.

Red flags that indicate an illegal or unsafe source

The compounded tirzepatide market includes legitimate pharmacies and predatory scams. Here are the red flags that indicate a source is illegal, unsafe, or both.

Red flag 1: No prescription required.

Any website that offers to sell tirzepatide (compounded or otherwise) without a prescription is breaking federal law. Some sites disguise this with a fake "medical questionnaire" that generates an automatic approval. If there is no live provider review and no opportunity for the provider to decline your request, it is not a real prescription.

Red flag 2: Shipping from overseas.

Compounded tirzepatide prepared by a U.S. 503A or 503B pharmacy ships from a U.S. address. If the tracking number shows origin in China, India, Eastern Europe, or any non-U.S. country, the product is not compounded tirzepatide. It is either counterfeit, diverted, or gray-market API sold directly to consumers. The FDA has issued multiple warning letters about overseas tirzepatide sold online.

Red flag 3: Price far below market.

If the price is under $250/month for maintenance doses, ask why. Legitimate compounding pharmacies have hard costs (API, labor, overhead, compliance) that set a floor around $280-$300. Prices significantly below that suggest the pharmacy is cutting corners (unregistered facility, non-sterile compounding, questionable API source) or the product is not tirzepatide at all.

Red flag 4: No pharmacist contact information.

Legitimate pharmacies have a licensed pharmacist available to answer questions. If the website has no phone number, or the phone number goes to a call center that cannot connect you to a pharmacist, do not order.

Red flag 5: Marketing language that makes equivalency claims.

Compounded tirzepatide is not equivalent to Mounjaro or Zepbound. If a website says "same as Mounjaro, just cheaper" or "generic Zepbound," it is misrepresenting the product. The FDA has sent warning letters to pharmacies making these claims.

Red flag 6: Vague or missing API source.

Ask where the tirzepatide comes from. If the pharmacy says "FDA-approved supplier" but will not name the supplier, or if they say "proprietary source," walk away. Legitimate pharmacies are transparent about API sourcing.

Red flag 7: No beyond-use date or expiration date on the vial.

Every compounded medication must have a beyond-use date. If the vial arrives with no date, or if the date is handwritten and illegible, the pharmacy is not following USP 797 standards.

Red flag 8: Offering tirzepatide in oral, nasal, or sublingual forms.

Tirzepatide is only effective as a subcutaneous injection. It is a peptide that breaks down in the digestive tract, so oral forms do not work. Any source offering "oral tirzepatide" is selling a fake product.

Red flag 9: No adverse event reporting process.

Legitimate pharmacies and telehealth platforms have a process for reporting side effects. If the website has no information about how to report adverse events, or if customer service dismisses your concerns, that is a red flag.

Red flag 10: Pressure tactics or urgency language.

"Limited supply, order now!" or "Shortage ending soon, stock up!" are sales tactics, not medical guidance. Legitimate providers do not pressure patients to order more medication than they need.

If you encounter any of these red flags, do not order. Report the website to the FDA's Health Fraud Program at fda.gov/consumers/health-fraud-scams/how-report-health-fraud.

Insurance coverage: why compounded tirzepatide is almost always cash-pay

Insurance coverage for compounded tirzepatide is rare. Here is why.

Medicare Part D explicitly excludes compounded drugs. The Part D statute prohibits coverage of compounded medications unless they contain at least one bulk ingredient not available in an FDA-approved form. Tirzepatide is available in FDA-approved forms (Mounjaro, Zepbound), so compounded tirzepatide does not meet the exception.

Commercial insurance plans rarely cover compounded medications. Most plans have formularies (lists of covered drugs) that include only FDA-approved products. Compounded drugs are typically excluded unless medically necessary (patient has a documented allergy to an inactive ingredient in the commercial product, for example).

Employer-sponsored plans have discretion but rarely exercise it. Self-insured employer plans can choose to cover compounded tirzepatide, but most do not because the cost savings to the patient do not translate to cost savings for the plan. The plan pays $1,060/month for Mounjaro or Zepbound (minus patient copay). If the plan covered compounded tirzepatide at $400/month, the plan saves money, but most plans have not updated their policies to allow this.

Prior authorization for brand-name tirzepatide does not extend to compounded versions. If your insurance approved Mounjaro or Zepbound, that approval does not apply to compounded tirzepatide. You would need a separate prior authorization, which most plans will deny.

FSA and HSA funds can be used for compounded tirzepatide. Flexible spending accounts and health savings accounts allow you to pay for prescription medications with pre-tax dollars. Compounded tirzepatide qualifies as long as you have a valid prescription. This effectively reduces the cost by your marginal tax rate (22% to 37% for most users).

Some patients get partial reimbursement through out-of-network benefits. If your plan has out-of-network pharmacy benefits, you can pay cash for compounded tirzepatide, then submit a claim for reimbursement. The plan will reimburse at the out-of-network rate (often 50% to 70% of the allowed amount after deductible). This is plan-specific and requires filing claims manually.

The practical reality: plan to pay cash. If you have an FSA or HSA, use that. If your plan has out-of-network benefits, try filing a claim, but do not count on reimbursement.

One exception: a few employer-sponsored plans have started covering compounded GLP-1 medications as a cost-containment strategy. This is more common in self-insured plans at large employers (10,000+ employees) with sophisticated pharmacy benefit consultants. If you work for a large employer, check with HR.

The decision tree: should you buy compounded or wait for brand-name

This decision depends on cost tolerance, insurance status, and risk tolerance. Here is the branching logic.

If your insurance covers Mounjaro or Zepbound with a copay under $100/month: → Use brand-name. The copay is lower than compounded cash price, and you get the FDA-approved product with the most clinical data.

If your insurance does not cover, or requires prior authorization you cannot get: → Continue to next question.

If you can afford $1,060/month out of pocket: → You can choose brand-name for the FDA-approved product and auto-injector convenience, or compounded to save $600+/month. Most patients in this situation choose compounded.

If you cannot afford $1,060/month but can afford $400-$500/month: → Compounded is the only realistic option. Verify the pharmacy carefully (see verification section above).

If you cannot afford $400/month: → Compounded tirzepatide is not accessible at that price point. Consider semaglutide (compounded semaglutide is often $250-$350/month), or explore patient assistance programs for brand-name products. Eli Lilly offers a savings card that reduces Mounjaro and Zepbound to $25/month for commercially insured patients who meet income requirements (under 400% of federal poverty level). Check LillyDirect.com for current programs.

If you have used brand-name tirzepatide and want to switch to compounded to save money: → Expect a transition period. Some patients report increased nausea or different injection site reactions when switching due to formulation differences. Plan to switch at a stable dose, not during titration. Monitor symptoms closely for the first 2-3 weeks.

If you have never used a GLP-1 medication and are choosing between compounded semaglutide and compounded tirzepatide: → Tirzepatide has superior weight-loss efficacy in head-to-head trials (Rosenstock et al., NEJM 2021). Compounded tirzepatide costs $100-$150 more per month than compounded semaglutide. If the cost difference is manageable, tirzepatide is the better choice for weight loss. If cost is the primary constraint, semaglutide is effective and cheaper.

If you are concerned about the legal or safety risk of compounded medications: → The legal risk to patients is near zero (the risk is to pharmacies operating improperly). The safety risk is real but manageable if you verify the pharmacy properly. If the risk feels unacceptable, wait for brand-name access or explore patient assistance programs.

What happens when the FDA shortage ends

The FDA will remove tirzepatide from the shortage list when Eli Lilly demonstrates sustained supply that meets projected demand. When that happens, the legal basis for compounding tirzepatide disappears.

The FDA has historically given compounding pharmacies 60 to 90 days' notice before removing a drug from the shortage list. During that window, pharmacies can continue compounding for existing patients but cannot take new patients.

After the removal date, compounding tirzepatide is only legal under narrow circumstances:

• Patient has a documented allergy to an inactive ingredient in Mounjaro or Zepbound
• Patient requires a dose not commercially available (uncommon, since Mounjaro and Zepbound cover 2.5 mg to 15 mg in 2.5 mg increments)
• Patient has a medical reason they cannot use an auto-injector pen (severe arthritis, visual impairment, etc.)

Most patients currently using compounded tirzepatide will need to switch to brand-name or discontinue treatment when the shortage ends.

What to do if you are on compounded tirzepatide when the shortage ends:

1. Check your insurance coverage for Mounjaro or Zepbound. If your plan covers it with prior authorization, start that process 60 days before the shortage removal date. Prior authorization can take 2-4 weeks.

1. Explore patient assistance programs. Eli Lilly's savings card and patient assistance foundation can reduce costs significantly for eligible patients.

1. Budget for the cost increase. If you will pay cash for brand-name, the jump from $400/month to $1,060/month is substantial. Plan accordingly.

1. Ask your provider about switching to semaglutide. If semaglutide remains on the shortage list longer than tirzepatide (possible, though not certain), compounded semaglutide may remain available. Semaglutide is less effective than tirzepatide but still produces meaningful weight loss.

1. Do not stockpile compounded tirzepatide. Some patients ask pharmacies to dispense 3-6 months' supply before the shortage ends. This is not advisable. Compounded tirzepatide has a 60- to 90-day beyond-use date. Medication compounded in April will expire by June or July. Stockpiling wastes money and risks using expired product.

The FDA has not announced a timeline for removing tirzepatide from the shortage list. Eli Lilly's Q4 2025 earnings call indicated that the company expects to meet demand by late 2026, but this is not a firm commitment. The shortage could end in Q3 2026, or it could extend into 2027.

FormBlends will notify patients if and when the FDA announces a shortage removal date. We will provide transition support, including insurance navigation and assistance applying for patient assistance programs.

FAQ

Can I buy compounded tirzepatide without a prescription? No. All legitimate sources require a prescription from a licensed provider. Any website offering tirzepatide without a prescription is operating illegally and selling product of unknown origin and safety.

Is compounded tirzepatide the same as Mounjaro or Zepbound? No. Compounded tirzepatide uses the same active ingredient but is not pharmaceutically equivalent. Differences include formulation, delivery method (vial vs pen), and stability data. Compounded versions are not FDA-approved and have not undergone the same clinical trials.

How much does compounded tirzepatide cost? Prices range from $299 to $549 per month depending on dose and whether you use a telehealth platform or go direct to a pharmacy. Most patients pay $399 to $499 monthly at maintenance doses (7.5 to 12.5 mg weekly).

Will my insurance cover compounded tirzepatide? Probably not. Medicare Part D excludes compounded drugs. Most commercial plans do not cover compounded medications. You can use FSA or HSA funds, and some plans allow out-of-network reimbursement, but most patients pay cash.

How do I know if a compounding pharmacy is legitimate? For 503B pharmacies, check the FDA's registered outsourcing facilities list. For 503A pharmacies, verify the state pharmacy license. Ask where they source tirzepatide, request third-party testing documentation, and confirm they follow USP 797 standards. Avoid pharmacies that refuse to provide this information.

Can I buy compounded tirzepatide from Canada or overseas? No. Compounded tirzepatide from overseas sources is illegal to import and is not subject to U.S. quality standards. The FDA has issued warnings about counterfeit tirzepatide sold online from overseas suppliers.

What is the difference between 503A and 503B pharmacies? 503A pharmacies are state-licensed and compound patient-specific prescriptions. 503B pharmacies are FDA-registered outsourcing facilities that can compound small batches and ship nationally. 503B facilities generally have stricter quality standards because they follow cGMP and undergo FDA inspection.

How long will compounded tirzepatide be available? As long as tirzepatide remains on the FDA drug shortage list. The FDA has not announced when the shortage will end. Industry analysts expect it to persist through Q3 2026 at minimum. When the shortage ends, compounding tirzepatide will only be legal under narrow patient-specific circumstances.

Can I switch from brand-name Mounjaro or Zepbound to compounded tirzepatide? Yes, but expect a transition period. Some patients report different side effects or efficacy when switching due to formulation differences. Switch at a stable dose, not during titration, and monitor symptoms closely for 2-3 weeks.

Do I need to refrigerate compounded tirzepatide? Yes. Tirzepatide must be stored refrigerated at 2-8°C (36-46°F). Do not freeze. Once opened, most compounded tirzepatide vials have a 28- to 30-day in-use period, though some pharmacies assign longer periods based on stability testing. Check the label.

Can I use compounded tirzepatide if I am pregnant or breastfeeding? No. Tirzepatide is not recommended during pregnancy or breastfeeding. Animal studies showed fetal harm. If you become pregnant while using tirzepatide, stop immediately and contact your provider.

What should I do if I experience severe side effects? Contact your provider immediately if you experience severe upper abdominal pain (possible pancreatitis), persistent vomiting beyond 24 hours, difficulty swallowing, or signs of an allergic reaction (rash, swelling, difficulty breathing). For severe symptoms, seek emergency care.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
3. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
4. U.S. Food and Drug Administration. Registered Outsourcing Facilities. Updated April 2026.
5. U.S. Food and Drug Administration. Compounding Laws and Policies. Federal Food, Drug, and Cosmetic Act Section 503A and 503B.
6. United States Pharmacopeia. General Chapter 797: Pharmaceutical Compounding - Sterile Preparations. 2019.
7. Eli Lilly and Company. Q4 2025 Earnings Call Transcript. February 2026.
8. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
9. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
10. National Association of Boards of Pharmacy. Compounding Pharmacy Accreditation. 2025.
11. U.S. Food and Drug Administration. Warning Letters on Compounded GLP-1 Medications. 2024-2026.
12. Centers for Medicare & Medicaid Services. Medicare Part D Coverage of Compounded Drugs. Policy Guidance. 2023.
13. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
14. U.S. Food and Drug Administration. Guidance for Industry: Compounding and the FDA. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. Pepcid, Tagamet, Prilosec, Nexium, and Protonix are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.